A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Anticoagulants

  • NEJM Publication: Edoxaban for VTE Treatment

    Stephan Moll, MD writes…  Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

  • International Coagulation Meeting (ISTH 2013): Highlights

    Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

  • Natural supplements, herbs, vitamins and food: do any prevent venous thromboembolism?

    Patients not infrequently inquire about the benefit of “natural blood thinners”. Clot Connect has written a document for patients – available here  – discussing the various herbs and dietary supplements that are often called “natural blood thinners”. The blog post discusses many items including garlic, gingko, chocolate, fish oil, vitamin D, vitamin E, etc. The…

  • FDA Approval of New Drug to Treat Major Bleeding on Warfarin – Kcentra

    Stephan Moll, MD writes…  A new drug for the urgent reversal of warfarin was approved by the FDA today, April 29th, 2013 (announcement by the FDA is here), called Kcentra.  The drug is derived from pooled plasma from healthy blood donors and contains the coagulation factors that are low in warfarin-treated patients, i.e. factors II, VII,…

  • Warfarin Failure

    Stephan Moll, MD writes… Occasionally, recurrent DVT or PE occur in spite of warfarin therapy, particularly in patients with (a) fluctuating and sub-therapeutic INRs, (b) lupus anticoagulant/ antiphospholipid antibody (APLA) syndrome or (c) cancer.

  • Apixaban (Eliquis) – Hospital Guideline

    Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban

  • Xarelto (Rivaroxaban) – Hospital Guideline

    Stephan Moll, MD writes… Xarelto® is FDA approved for treatment of venous thromboembolism (VTE), prevention of VTE after hip and knee replacement  surgery, and for atrial fibrillation.   A number of practical management questions are encountered by physicians, pharmacists, and other health care professional taking care of patients on Xarelto®, such as (a) dosing in…

  • FDA Approval for Apixaban (Eliquis) for A. Fib.

    Stephan Moll, MD writes… Today (Dec 28th, 2012) the FDA approved apixaban for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation, based on the ARISTOTLE study [ref 1].  The FDA press release is here.